Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer treatment—SkinJect, a novel microneedle patch designed to eradicate cancerous cells ...
Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical for advanced hepatocellular carcinoma. The therapy uses a GPC3-targeting ...
BioNTech SE and Bristol Myers Squibb have partnered to co-develop and co-commercialize BNT327, a next-generation bispecific antibody targeting PD-L1 and VEGF-A in over 10 solid tumor indications. The ...
GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell lung cancer, supported by early ARTEMIS 001 data showing durable responses in ...
The START Center for Cancer Research dosed the first U.S. patient in Moderna’s Phase 1 trial of mRNA-4106, a multivalent mRNA-based cancer vaccine targeting advanced solid tumors. The study evaluates ...
Longer-term follow-up from the Phase 1b/2 OrigAMI-1 study shows that amivantamab (Rybrevant) plus FOLFOX or FOLFIRI achieved a 51% overall response rate in RAS/BRAF wild-type metastatic colorectal ...
Rznomics has received FDA Orphan Drug Designation for RZ-001, a novel RNA-based therapy for Hepatocellular carcinoma. RZ-001 employs advanced RNA editing to target and suppress cancer growth, showing ...
Despite two decades of clinical experience with Everolimus in transplant medicine, cancer patients continue to face preventable toxicities and fatal adverse events. While transplant patients benefit ...
Researchers at Cold Spring Harbor Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma. Splice-switching antisense oligonucleotides targeting AURKA 5′ ...
The application for nipocalimab was submitted to the FDA for the treatment of generalized myasthenia gravis (gMG), following promising results from the Phase 3 Vivacity-MG3 study. This ...
Everest Medicines' licensing partner Calliditas Therapeutics announced that the FDA approved Nefecon to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at ...
Novartis has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, marking another major step in its $23 billion U.S. expansion plan. The site, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results